Breaking News

CMP Pharma, Kiel Labs In Drug Development Pact

By Kristin Brooks | March 3, 2014

To develop two NDA products in liquid dosage form

CMP Pharma and Kiel Laboratories have signed an agreement to develop and commercialize two new drug products. Both drugs are approved by the FDA in solid dosage forms and CMP will file NDAs to gain approval for an alternate liquid dosage form.
 
CMP Pharma is a specialty pharmaceutical company located in Farmville, NC that develops and manufactures a portfolio of high-value topical and liquid pharmaceutical products. Kiel Laboratories, Inc., located in Flowery Branch, GA, provides drug development, regulatory and intellectual property services, and specializes in identification of and regulatory strategies around 505(b)(2) NDA submissions.     
 
Gerald Sakowski, chief executive officer of CMP Pharma, said, “These two products are excellent complements to our line of niche specialty pharmaceutical products. This is another chapter in our long history of developing stable, ready-to-use liquid dosage forms that make life easier on the consumer, the physician and the pharmacist.”

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Tackling Drug Serialization Challenges

    Tackling Drug Serialization Challenges

    Tim Wright, editor||January 22, 2016
    Siemens and Adents together will develop a combined hardware plus software solution for pharma industry

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016